Oseltamavir: Difference between revisions
(11 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: Antiviral - neuraminidase inhibitor | ||
*Dosage Forms: | *Dosage Forms: capsule (30, 45, 75mg), powder for PO susp (6mg/mL) | ||
*Common Trade Names: | *Common Trade Names: Tamiflu | ||
==Adult Dosing== | ==Adult Dosing== | ||
Line 10: | Line 10: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
''5 day course'' | ''5 day course'' | ||
*1-8 months: | *1-8 months: 3mg/kg PO BID | ||
*9-23 months: 3. | *9-23 months: 3.5mg/kg PO BID | ||
*2-12 years: | *2-12 years: | ||
**<15kg: | **<15kg: 30mg PO BID | ||
**16-23kg: | **16-23kg: 45mg PO BID | ||
**24-40kg: | **24-40kg: 60mg PO BID | ||
**>40kg: | **>40kg: 75mg PO BID | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: Category C | ||
*Lactation: | *Lactation: Unknown; caution required | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult | ||
Line 33: | Line 33: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
Rare <1% | |||
Arrhythmia, delirium, hemorrhagic colitis, hepatitis, seizure, TEN, SJS, angioedema, unstable angina, pseudomembranous colitis | |||
===Common=== | ===Common=== | ||
Abdominal pain, insomnia, nausea, vomitting, vertigo, epistaxis, ear complaints, conjunctivitis. | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 1-3 hrs (oseltamivir); 6-10hrs oseltamivir carboxylate) | ||
*Metabolism: | *Metabolism: hepatic | ||
*Excretion: | *Excretion: urine/stool | ||
*Mechanism of Action: | *Mechanism of Action: competitive inhibition of influenza virus neuraminidase enzyme, effectively halting viral release from infected cells and passing through mucus membranes. | ||
==See Also== | ==See Also== | ||
==References== | |||
<references/> | <references/> | ||
[[Category: | |||
[[Category:Pharmacology]] |
Revision as of 03:50, 1 November 2017
General
- Type: Antiviral - neuraminidase inhibitor
- Dosage Forms: capsule (30, 45, 75mg), powder for PO susp (6mg/mL)
- Common Trade Names: Tamiflu
Adult Dosing
Influenza
75mg PO BID x5d
Pediatric Dosing
5 day course
- 1-8 months: 3mg/kg PO BID
- 9-23 months: 3.5mg/kg PO BID
- 2-12 years:
- <15kg: 30mg PO BID
- 16-23kg: 45mg PO BID
- 24-40kg: 60mg PO BID
- >40kg: 75mg PO BID
Special Populations
- Pregnancy Rating: Category C
- Lactation: Unknown; caution required
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Rare <1%
Arrhythmia, delirium, hemorrhagic colitis, hepatitis, seizure, TEN, SJS, angioedema, unstable angina, pseudomembranous colitis
Common
Abdominal pain, insomnia, nausea, vomitting, vertigo, epistaxis, ear complaints, conjunctivitis.
Pharmacology
- Half-life: 1-3 hrs (oseltamivir); 6-10hrs oseltamivir carboxylate)
- Metabolism: hepatic
- Excretion: urine/stool
- Mechanism of Action: competitive inhibition of influenza virus neuraminidase enzyme, effectively halting viral release from infected cells and passing through mucus membranes.